Toxicity-reducing potential of extracorporeal affinity adsorption treatment in combination with the auristatin-conjugated monoclonal antibody BR96 in a syngeneic rat tumor model-Reference-Cited by-同舟云学术

Toxicity-reducing potential of extracorporeal affinity adsorption treatment in combination with the auristatin-conjugated monoclonal antibody BR96 in a syngeneic rat tumor model

Published:2010-02-02 Issue:S4 Volume:116 Page:1033-1042
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Nilsson Rune,Mårtensson Linda,Eriksson Sophie E.,Sjögren Hans-Olov,Tennvall Jan

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.24790/fullpdf

Reference14 articles.

1. Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma;Vaishampayan;Clin Cancer Res,2000

2. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity;Doronina;Bioconjug Chem,2006

3. Extracorporeal immunoadsorption therapy on rats. In vivo depletion of specific antibodies;Nilsson;Clin Exp Immunol,1990

4. Extracorporeal immunoadsorption from whole blood based on the avidin-biotin concept. Evaluation of a new method;Garkavij;Acta Oncol,1996

5. A nonsurgical technique for blood access in extracorporeal affinity adsorption of antibodies in rats;Martensson;Artif Organs,2007

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antibody-Based Biotherapeutics in Cancer;Pharmaceutical Biotechnology;2024

2. Anti-glypican-1 antibody–drug conjugate is a potential therapy against pancreatic cancer;British Journal of Cancer;2020-03-10

3. Anti‐glypican‐1 antibody‐drug conjugate exhibits potent preclinical antitumor activity against glypican‐1 positive uterine cervical cancer;International Journal of Cancer;2017-10-31

4. Chemical and Genetic Modification;Pharmaceutical Sciences Encyclopedia;2013-11-25

5. Treatment with Unlabeled mAb BR96 After Radioimmunotherapy with 177Lu-DOTA-BR96 in a Syngeneic Rat Colon Carcinoma Model;Cancer Biotherapy and Radiopharmaceuticals;2012-04